Octagon Capital Advisors »

Evommune shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Evommune (EVMN) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Evommune

Tip: Access up to 7 years of quarterly data

All positions including Evommune held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Evommune by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $8.6M 500k 17.12

More positions owned by Octagon Capital Advisors

Abivax Sa Sponsored Ads (ABVX)
Dianthus Therapeutics (DNTH)
Cogent Biosciences (COGT)
Taysha Gene Therapies Com Shs (TSHA)
Gossamer Bio (GOSS)
Kymera Therapeutics (KYMR)
Arrivent Biopharma (AVBP)
Trevi Therapeutics (TRVI)
Ocular Therapeutix (OCUL)
Mind Medicine Mindmed Com New (MNMD)
Cg Oncology Call Option (CGON)
Alumis (ALMS)
Palisade Bio (PALI)
Cidara Therapeutics Com New (CDTX)
Bioage Labs (BIOA)

View all positions for Octagon Capital Advisors

Top funds holding Evommune

EQT Fund Management S.a r.l.
RA Capital Management
Pivotal bioVenture Partners Investment Advisor
Nan Fung Group Holdings
Rtw Investments
Marshall Wace
Eventide Asset Management
Sectoral Asset Management
Verition Fund Management
Standard Life Aberdeen
Velan Capital Investment Management
Vanguard Group
Octagon Capital Advisors
American Century Companies
Federated Investors

View all funds holding Evommune